Hydroxychloroquine alone and a combination of hydroxychloroquine and azithromycin were shown to be more effective than the control in treating patients with COVID-19 virus in a small sample non-randomized study reported by Gautret et al. [1]. Hydroxychloroquine, approved by the Food and Drug Administration (FDA) as an anti-malarial drug, was repurposed to treat patients with COVID-19 virus. This important finding along with results from other treatments (e.g., Chloroquine) may point out a path to end the coronavirus pandemic. However, we find that the statistical analyses by Gautret et al. [1] are inappropriate. One of the three goals of this letter is to fix the errors so that their promising clinical results are properly interpreted. A follow-up large-scale clinical trial has started in the United States to confirm its activity [2]. For an early phase clinical trial, proper and efficient statistical methods would provide valid results and novel study designs to speed up the treatment discovery.